Nexalin Reports 77.8% Anxiety Response Rate in Brazil Trial, Paving Way for Product Launch
NXL sits 47% above its 52-week low of $0.305 on light trading volume (0.2× avg).
Summary
Nexalin Technology announced compelling clinical trial results in Brazil for its neurostimulation device, demonstrating a 77.8% anxiety response rate and durable benefits across depression, insomnia, and quality of life. This positive data supports the company's plan for a product launch and sales campaign in Brazil. For a micro-cap company facing a going concern warning and Nasdaq delisting threats, these strong clinical results and a clear path to market entry in a new region are a material positive development, offering potential revenue and validation for its technology.
At the time of this announcement, NXL was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.31 to $2.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.